Dr. El-Fass has completed a 9-months fellowship in Health Economics from ISPOR-Egypt  and Wifor Institute (Germany). Additionally, He was assigned as a reviewer for research  projects submitted for ISPOR Europe Conference 2020.  

Dr. El-Fass's primary research interest is pharmacoeconomic evaluation, pharmacoepidemiologic research on medication safety and medication use and pharmaceutical services research. 

Recent research activities: 

1. The impact of introducing a clinical pharmacy services program in the  hemodialysis unit in a facility with economic constraints. Reem Nagib, Kareem El Fass, Maha Abdul-Latif, Hoda Sakoury. (Abstract published in Journal of the  American College of Clinical Pharmacy 2020; 3(1),145-391) 

2. Evaluation of Spontaneous Adverse Event Reports for Osteonecrosis of the Jaw  (ONJ) Attributed to Denosumab and Zoledronic Acid Within the FDA Adverse  Events Reporting System (FAERS). Mohamed A. Mekkawy, Kareem El-Fass,  Reem Nagib Mohammad and Adel Abou-Ali (abstract published in 

pharmacoepidemiology and drug safety 2017; 26(Suppl. 2): 3–636)